Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel ...

FDA final guidance sets a risk-based potency assurance roadmap for cell and gene therapies, spanning development, ...

PCR assay development often involves separate steps for consumables, reagents, and instrumentation, making the path from prototype to production more complex. An integrated workflow connects these ...

As the biologics landscape becomes increasingly complex and therapeutic modalities grow more sophisticated, potency assay strategies are evolving from regulatory requirements into powerful tools that ...

Since biological therapeutics are derived from living organisms, their manufacture and validation presents difficulties not encountered during traditional small molecule drug development. Despite the ...

The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provide quick results while delivering expected performance and ...

Optimizing PCR assays for assay development (AD) workflows typically involves a range of interdependent factors. These include thermocycling conditions, enzyme levels, buffer chemistry, and ...

Lateral flow assays are an area of intense research and have led to highly robust and sensitive products, proving themselves indispensable for rapid diagnostics. Advancements in technologies used for ...

Lateral flow assay applications have become increasingly diverse in a post-pandemic world, and the areas of infectious disease and oncology continue to be at the forefront. In both areas, the use of ...

Biomarker discovery and research is a rapidly growing healthcare field that continues to impact the healthcare system significantly. Biomarker research has been used in preclinical research settings ...